Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach.

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Sodium glucose co-transporter-2 (SGLT2) inhibitors were initially developed for diabetes management.
• These drugs exhibit antihyperglycemic, diuretic, cardioprotective, and renoprotective effects.
• Emerging evidence suggests broader therapeutic applications beyond glycemic control.

Approach:

• This review employs a case-based methodology.
• It focuses on the expanded indications of SGLT2 inhibitors.
• The review specifically examines patients without diabetes.

Key Points:

• SGLT2 inhibitors demonstrate significant benefits in heart failure management.
• These agents show promise in slowing the progression of chronic kidney disease.
• Therapeutic potential extends to non-diabetic individuals with these conditions.

Conclusions:

• SGLT2 inhibitors represent a versatile therapeutic class with expanding roles.
• Their utility in heart failure and chronic kidney disease is increasingly recognized.
• Further research may uncover additional applications for SGLT2 inhibitors in diverse patient populations.